Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Carbidopa,Etilevodopa,Entacapone
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Erik Selin
Deal Size : $17.0 million
Deal Type : Series A Financing
Details : Proceeds from the financing will enable Intrance to initiate pivotal U.S. clinical trials for the company’s lead product, Lecigon® (in the Nordic countries and European markets) for enteral infusion (light weight infusion pump) in advanced Parkinsonâ€...
Brand Name : Lecigon
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 04, 2022
Lead Product(s) : Carbidopa,Etilevodopa,Entacapone
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Erik Selin
Deal Size : $17.0 million
Deal Type : Series A Financing
Lead Product(s) : Etilevodopa,Carbidopa,Entacapone
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
STADA Launches Novel Parkinson’s Therapy in Germany and Austria
Details : The novel gel formulation is of the three established Parkinson's active ingredients levodopa, carbidopa and entacapone has a positive effect on the bioavailability of levodopa in the body.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 15, 2021
Lead Product(s) : Etilevodopa,Carbidopa,Entacapone
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Etilevodopa,Carbidopa,Entacapone
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : STADA Arzneimittel
Deal Size : Undisclosed
Deal Type : Acquisition
Details : By acquiring Lobsor Pharmaceuticals, STADA gains rights to a triple fixed combination (levodopa, carbidopa, entacapone), delivered via modern pump technology, that has already been successfully launched in Nordic countries.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 02, 2020
Lead Product(s) : Etilevodopa,Carbidopa,Entacapone
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : STADA Arzneimittel
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?